Report Cover

U.S. Heparin Market Size By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026


The U.S. heparin market is likely to gain substantial momentum over the coming years owing to the increasing incidences of venous thromboembolism and genetic risk factors among the population. Heparin is known as an essential anticoagulant and is mainly used to prevent and treat blood clots which are caused by specific medical procedures or conditions. 

Heparin is an extremely sulfated glycosaminoglycan and the most negatively charged biological molecule ever known. Heparin further aid to keep the blood flowing smoothly into the body by making a specific natural substance in the body known as anti-clotting protein. 

In addition, heparin is also utilized to produce an anti-clotting surface inside numerous medical devices like test tubes, renal dialysis machines among others. According to the data published in the Centers for Disease Control and Prevention, approximately 900,000 people in U.S. are affected by pulmonary embolism and deep vein thrombosis. Further estimates suggest that around 60,000-100,000 Americans die of DVT/PE. This factor is anticipated to propel the regional demand in the forthcoming years.

The U.S. heparin market is segmented in terms of product, application, and distribution channel. 

With respect to product, the U.S. heparin market is classified into unfractionated heparin and low molecular weight heparin. Among these products, unfractionated heparin segment accounted for a revenue share of approximately $87.7 million. UFH or unfractionated heparin is essentially a fast-acting blood thinner that works with antithrombin, known to be a natural protein in the human body for blocking the clot formation. 

The segment is likely to witness lucrative growth over the coming years since it is inexpensive in comparison to other heparin formulations. UFH swiftly enters the blood stream and acts rapidly to stop formation of clots. It also wears off when the injections or infusion are stopped. These factors are thus likely to contribute towards segmental growth in the coming years.

In terms of application, the overall U.S. heparin market is categorized into coronary artery disease, venous thromboembolism, atrial fibrillation/flutter, and others. Among these, venous thromboembolism segment will witness considerable growth over the coming years. In 2019, the segment accounted for a market share of over 52.6%. UFH is being substituted by low-molecular-weight heparin as the most essential anticoagulant of choice for the initial treatment of patients with venous thromboembolism. 

Based on distribution channel, the overall U.S. heparin market is bifurcated into online pharmacy, retail pharmacy, and hospital pharmacy. Among these, the hospital pharmacy segment will exhibit a market growth of more than 6.8% CAGR through the analysis timeframe.
Report Content
Chapter 1   Methodology
1.1    Market definitions
1.2    Base estimates & working
1.3    Forecast calculations
1.4    Data validation
1.5    Data sources
1.5.1    Secondary
1.5.1.1    Paid sources
1.5.1.2    Unpaid sources
1.5.2    Primary
Chapter 2   Executive Summary
2.1    U.S. heparin industry 360 degree synopsis, 2015-2026
2.1.1    Business trends
Chapter 3   US Heparin Industry Insights
3.1    Industry segmentation
3.2    Industry landscape, 2015 - 2026
3.3    Industry impact forces
3.3.1    Growth drivers
3.3.1.1    Growing prevalence of chronic diseases
3.3.1.2    High demand for anti-coagulant products
3.3.1.3    Rising geriatric population in U.S.
3.3.2    Industry pitfalls & challenges
3.3.2.1    High risk of side effects
3.3.2.2    High dependency on porcine
3.4    Growth potential analysis
3.4.1    By product
3.4.2    By application
3.4.3    By distribution channel
3.5    COVID-19 impact analysis
3.6    Porter's analysis
3.7    Competitive landscape, 2019
3.7.1    Company share analysis, 2019
3.7.2    Company matrix analysis
3.8    PESTEL analysis
Chapter 4   US Heparin Market, By Product
4.1    Key segment trends
4.2    Low molecular weight heparin
4.2.1    Market size, 2015 - 2026 (USD Million)
4.3    Unfractionated heparin
4.3.1    Market size, 2015 - 2026 (USD Million)
Chapter 5   US Heparin Market, By Application 
5.1    Key segment trends
5.2    Venous thromboembolism
5.2.1    Market size, 2015 - 2026 (USD Million)
5.3    Atrial fibrillation/flutter
5.3.1    Market size, 2015 - 2026 (USD Million)
5.4    Coronary artery disease
5.4.1    Market size, 2015 - 2026 (USD Million)
5.5    Others
5.5.1    Market size, 2015 - 2026 (USD Million)
Chapter 6   US Heparin Market, By Distribution Channel 
6.1    Key segment trends
6.2    Hospital pharmacy
6.2.1    Market size, 2015 - 2026 (USD Million)
6.3    Retail pharmacy
6.3.1    Market size, 2015 - 2026 (USD Million)
6.4    Online pharmacy
6.4.1    Market size, 2015 - 2026 (USD Million)
Chapter 7   Company Profiles
7.1    Competitive dashboard, 2019
7.2    Amphastar Pharmaceutical
7.2.1    Business overview
7.2.2    Financial data
7.2.3    Product landscape
7.2.4    Strategic outlook
7.2.5    SWOT analysis
7.3    Changzhou Qianhong Biopharma Co , Ltd
7.3.1    Business overview
7.3.2    Financial data
7.3.3    Product landscape
7.3.4    Strategic outlook
7.3.5    SWOT analysis
7.4    Fresenius Kabi
7.4.1    Business overview
7.4.2    Financial data
7.4.3    Product landscape
7.4.4    Strategic outlook
7.4.5    SWOT analysis
7.5    Leo Pharma A/S
7.5.1    Business overview
7.5.2    Financial data
7.5.3    Product landscape
7.5.4    Strategic outlook
7.5.5    SWOT analysis
7.6    Nanjing King-Friend Biochemical Pharmaceutical
7.6.1    Business overview
7.6.2    Financial data
7.6.3    Product landscape
7.6.4    Strategic outlook
7.6.5    SWOT analysis
7.7    Pfizer, Inc
7.7.1    Business overview
7.7.2    Financial data
7.7.3    Product landscape
7.7.4    Strategic outlook
7.7.5    SWOT analysis
7.8    Sanofi
7.8.1    Business overview
7.8.2    Financial data
7.8.3    Product landscape
7.8.4    Strategic outlook
7.8.5    SWOT analysis
7.9    Shenzhen Hepalink
7.9.1    Business overview
7.9.2    Financial data
7.9.3    Product landscape
7.9.4    Strategic outlook
7.9.5    SWOT analysis
7.10    Yantai Dongcheng Biochemical Co , Ltd
7.10.1    Business overview
7.10.2    Financial data
7.10.3    Product landscape
7.10.4    Strategic outlook
7.10.5    SWOT analysis

Data Tables TABLE 1 U.S. heparin market size, 2015 - 2026 (USD Million) TABLE 2 U.S. heparin market size, 2015 - 2019 (USD Million) TABLE 3 Industry impact forces TABLE 4 U.S. low molecular weight heparin market size, 2015 - 2019 (USD Million) TABLE 5 U.S. low molecular weight heparin market size, 2020 - 2026 (USD Million) TABLE 6 U.S. unfractionated heparin market size, 2015 - 2019 (USD Million) TABLE 7 U.S. unfractionated heparin market size, 2020 - 2026 (USD Million) TABLE 8 U.S. venous thromboembolism market size, 2015 - 2019 (USD Million) TABLE 9 U.S. venous thromboembolism market size, 2020 - 2026 (USD Million) TABLE 10 U.S. atrial fibrillation/flutter market size, 2015 - 2019 (USD Million) TABLE 11 U.S. atrial fibrillation/flutter market size, 2020 - 2026 (USD Million) TABLE 12 U.S. coronary heart disease market size, 2015 - 2019 (USD Million) TABLE 13 U.S. coronary heart disease market size, 2020 - 2026 (USD Million) TABLE 14 Others market size, 2015 - 2019 (USD Million) TABLE 15 Others market size, 2020 - 2026 (USD Million) TABLE 16 U.S. hospital pharmacy market size, 2015 - 2019 (USD Million) TABLE 17 U.S. hospital pharmacy market size, 2020 - 2026 (USD Million) TABLE 18 U.S. retail pharmacy market size, 2015 - 2019 (USD Million) TABLE 19 U.S. retail pharmacy market size, 2020 - 2026 (USD Million) TABLE 20 U.S. online pharmacy market size, 2015 - 2019 (USD Million) TABLE 21 U.S. online pharmacy market size, 2020 - 2026 (USD Million) Charts & Figures FIG. 1 Top-down approach FIG. 2 Breakdown of primary participants FIG. 3 U.S. heparin industry 360 degree synopsis FIG. 4 Industry segmentation FIG. 5 U.S. heparin market, 2015 - 2026 (USD Million) FIG. 6 Growth potential analysis, by product FIG. 7 Growth potential analysis, by application FIG. 8 Growth potential analysis, by distribution channel FIG. 9 Porter's analysis FIG. 10 U.S. company share analysis, 2019 FIG. 11 Company matrix analysis, 2019 FIG. 12 PESTEL analysis FIG. 13 Key segment trends, by product FIG. 14 Key segment trends, by application FIG. 15 Key segment trends, by distribution channel FIG. 16 Competitive dashboard, 2019

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:
Publisher: Global Market Insights, Inc.
Chat with us